|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Power DG, Kelsen DP and Shah MA: Advanced
gastric cancer-slow but steady progress. Cancer Treat Rev.
36:384–392. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xuan Y, Hur H, Ham IH, Yun J, Lee JY, Shim
W, Kim YB, Lee G, Han SU and Cho YK: Dichloroacetate attenuates
hypoxia-induced resistance to 5-fluorouracil in gastric cancer
through the regulation of glucose metabolism. Exp Cell Res.
321:219–230. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Willers H, Azzoli CG, Santivasi WL and Xia
F: Basic mechanisms of therapeutic resistance to radiation and
chemotherapy in lung cancer. Cancer J. 19:200–207. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brown LM, Cowen RL, Debray C, Eustace A,
Erler JT, Sheppard FC, Parker CA, Stratford IJ and Williams KJ:
Reversing hypoxic cell chemoresistance in vitro using genetic and
small molecule approaches targeting hypoxia inducible factor-1. Mol
Pharmacol. 69:411–418. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu L, Ning X, Sun L, Zhang H, Shi Y, Guo
C, Han S, Liu J, Sun S, Han Z, et al: Hypoxia-inducible factor-1
alpha contributes to hypoxia-induced chemoresistance in gastric
cancer. Cancer Sci. 99:121–128. 2008.PubMed/NCBI
|
|
7
|
Hao J, Song X, Song B, Liu Y, Wei L, Wang
X and Yu J: Effects of lentivirus-mediated HIF-1alpha knockdown on
hypoxia-related cisplatin resistance and their dependence on p53
status in fibrosarcoma cells. Cancer Gene Ther. 15:449–455. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nardinocchi L, Puca R, Sacchi A and
D'Orazi G: Inhibition of HIF-1alpha activity by
homeodomain-interacting protein kinase-2 correlates with
sensitization of chemoresistant cells to undergo apoptosis. Mol
Cancer. 8:12009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Semenza GL: Hypoxia, clonal selection, and
the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol.
35:71–103. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Semenza GL: HIF-1 and tumor progression:
Pathophysiology and therapeutics. Trends Mol Med. 8 (4
Suppl):S62–S67. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mayer A and Vaupel P: Hypoxia, lactate
accumulation, and acidosis: Siblings or accomplices driving tumor
progression and resistance to therapy? Adv Exp Med Biol.
789:203–209. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wafik SE: Impact of genetic targets on
cancer therapy. Springer; New York: 2013
|
|
13
|
Serakinci N, Fahrioglu U and Christensen
R: Mesenchymal stem cells, cancer challenges and new directions.
Eur J Cancer. 50:1522–1530. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ren C, Kumar S, Chanda D, Chen J, Mountz
JD and Ponnazhagan S: Therapeutic potential of mesenchymal stem
cells producing interferon-alpha in a mouse melanoma lung
metastasis model. Stem Cells. 26:2332–2338. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li X, Lu Y, Huang W, Xu H, Chen X, Geng Q,
Fan H, Tan Y, Xue G and Jiang X: In vitro effect of
adenovirus-mediated human Gamma Interferon gene transfer into human
mesenchymal stem cells for chronic myelogenous leukemia. Hematol
Oncol. 24:151–158. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao P, Ding Q, Wu Z, Jiang H and Fang Z:
Therapeutic potential of human mesenchymal stem cells producing
IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer
Lett. 290:157–166. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Seo SH, Kim KS, Park SH, Suh YS, Kim SJ,
Jeun SS and Sung YC: The effects of mesenchymal stem cells injected
via different routes on modified IL-12-mediated antitumor activity.
Gene Ther. 18:488–495. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Grisendi G, Bussolari R, Cafarelli L,
Petak I, Rasini V, Veronesi E, De Santis G, Spano C, Tagliazzucchi
M, Barti-Juhasz H, et al: Adipose-derived mesenchymal stem cells as
stable source of tumor necrosis factor-related apoptosis-inducing
ligand delivery for cancer therapy. Cancer Res. 70:3718–3729. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang B, Shan H, Li D, Li ZR, Zhu KS and
Jiang ZB: The inhibitory effect of MSCs expressing TRAIL as a
cellular delivery vehicle in combination with cisplatin on
hepatocellular carcinoma. Cancer Biol Ther. 13:1175–1184. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chan WT, Verma CS, Lane DP and Gan SK: A
comparison and optimization of methods and factors affecting the
transformation of Escherichia coli. Biosci Rep. 33(pii):
e000862013.PubMed/NCBI
|
|
21
|
Ji RC: Hypoxia and lymphangiogenesis in
tumor microenvironment and metastasis. Cancer Lett. 346:6–16. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shannon AM, Bouchier-Hayes DJ, Condron CM
and Toomey D: Tumour hypoxia, chemotherapeutic resistance and
hypoxia-related therapies. Cancer Treat Rev. 29:297–307. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bubnovskaya L, Osinsky D, Trachevsky V,
Naleskina L, Kovelskaya A and Gumenyuk L: Premorphological
alterations in gastric mucosa in patients with gastric cancer:
Hypoxia level assessed by 31P NMR spectroscopy. Exp Oncol.
36:271–275. 2014.PubMed/NCBI
|
|
24
|
Höckel M and Vaupel P: Tumor hypoxia:
Definitions and current clinical, biologic, and molecular aspects.
J Natl Cancer Inst. 93:266–276. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Teicher BA: Hypoxia and drug resistance.
Cancer Metastasis Rev. 13:139–168. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nakamura J, Kitajima Y, Kai K, Hashiguchi
K, Hiraki M, Noshiro H and Miyazaki K: HIF-1alpha is an unfavorable
determinant of relapse in gastric cancer patients who underwent
curative surgery followed by adjuvant 5-FU chemotherapy. Int J
Cancer. 127:1158–1171. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Di Caprio G, Stokes C, Higgins JM and
Schonbrun E: Single-cell measurement of red blood cell oxygen
affinity. Proc Natl Acad Sci USA. 12:9984–9989. 2015. View Article : Google Scholar
|
|
29
|
Dicato M, Duham C, Berchem G and Ries F:
Clinical benefit from erythropoietin. Curr Opin Oncol. 12:297–302.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Väänänen HK: Mesenchymal stem cells. Ann
Med. 37:469–479. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Murphy MB, Moncivais K and Caplan AI:
Mesenchymal stem cells: Environmentally responsive therapeutics for
regenerative medicine. Exp Mol Med. 45:e542013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Loebinger MR, Kyrtatos PG, Turmaine M,
Price AN, Pankhurst Q, Lythgoe MF and Janes SM: Magnetic resonance
imaging of mesenchymal stem cells homing to pulmonary metastases
using biocompatible magnetic nanoparticles. Cancer Res.
69:8862–8867. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sasportas LS, Kasmieh R, Wakimoto H,
Hingtgen S, van de Water JA, Mohapatra G, Figueiredo JL, Martuza
RL, Weissleder R and Shah K: Assessment of therapeutic efficacy and
fate of engineered human mesenchymal stem cells for cancer therapy.
Proc Natl Acad Sci USA. 106:4822–4827. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang B, Wu X, Mao Y, Bao W, Gao L, Zhou P,
Xie R, Zhou L and Zhu J: Dual-targeted antitumor effects against
brainstem glioma by intravenous delivery of tumor necrosis
factor-related, apoptosis-inducing, ligand-engineered human
mesenchymal stem cells. Neurosurgery. 65:610–624. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tse WT, Pendleton JD, Beyer WM, Egalka MC
and Guinan EC: Suppression of allogeneic T-cell proliferation by
human marrow stromal cells: Implications in transplantation.
Transplantation. 75:389–397. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Corcione A, Benvenuto F, Ferretti E,
Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi
GL, Pistoia V and Uccelli A: Human mesenchymal stem cells modulate
B-cell functions. Blood. 107:367–372. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tsimberidou AM: Targeted therapy in
cancer. Cancer Chemother Pharmacol. 76:1113–1132. 2015. View Article : Google Scholar : PubMed/NCBI
|
